Jinhua Wang, Ph.D.
Affiliations: | 2006 | Utah State University, Logan, UT, United States |
Area:
Organic Chemistry, Biochemistry, ImmunologyGoogle:
"Jinhua Wang"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Cheng-Wei Tom Chang | grad student | 2006 | Utah State University | |
| (Design, synthesis, and structure activity relationship study of novel pyranmycins, kanamycin analogs and trehalose derivatives.) | ||||
| Nathanael Gray | research scientist | 2008- | Dana-Farber Cancer Institute and Harvard Medical School | |
Collaborators
Sign in to add collaborator| Jinwei Zhang | collaborator | Utah State University (Physiology Academic Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lantermans HC, Ma F, Kuil A, et al. (2024) The dual HCK/BTK inhibitor KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma. Leukemia |
| Wang L, Bohmer MJ, Wang J, et al. (2024) Discovery of Potent Antimalarial Type II Kinase Inhibitors with Selectivity over Human Kinases. Journal of Medicinal Chemistry |
| Bohmer MJ, Wang J, Istvan ES, et al. (2023) Human Polo-like Kinase Inhibitors as Antiplasmodials. Acs Infectious Diseases |
| Teng M, Jiang J, Wang ES, et al. (2023) Targeting the Dark Lipid Kinase PIP4K2C with a Potent and Selective Binder and Degrader. Angewandte Chemie (International Ed. in English). e202302364 |
| Zhang J, Pearson AJ, Sabherwal N, et al. (2022) Inhibiting ERK5 overcomes breast cancer resistance to anti-HER2 therapy by targeting the G1/S cell cycle transition. Cancer Research Communications. 2: 131-145 |
| Boytz R, Słabicki M, Ramaswamy S, et al. (2022) Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy. Journal of Medical Virology |
| Morita K, He S, Nowak RP, et al. (2022) Retraction Notice to: Allosteric Activators of Protein Phosphatase 2A Display Broad Antitumor Activity Mediated by Dephosphorylation of MYBL2. Cell. 185: 3058 |
| Li Z, Ishida R, Liu Y, et al. (2022) Synthesis and Structure-Activity relationships of cyclin-dependent kinase 11 inhibitors based on a diaminothiazole scaffold. European Journal of Medicinal Chemistry. 238: 114433 |
| Munshi M, Liu X, Kofides A, et al. (2022) A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Advances |
| Privalsky TM, Soohoo AM, Wang J, et al. (2021) Prospects for Antibacterial Discovery and Development. Journal of the American Chemical Society. 143: 21127-21142 |